SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to anticipation surrounding its upcoming earnings report, with the community actively discussing potential outcomes and guidance. Bullish sentiment suggests the company will beat expectations, driven by strong global adoption of its da Vinci systems and procedure growth, despite concerns about tariffs and margin pressures. Traders are also closely monitoring unusual options activity and technical indicators for potential short-term opportunities.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its latest earnings report, with revenue exceeding expectations but EPS falling slightly short, leading to mixed sentiment. The community is actively discussing whether the results justify the stock's valuation amidst broader concerns about the macro environment and potential tariff impacts. Some believe TXN is undervalued and poised for a rally, while others are wary of the company's guidance and competitive landscape.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

Sweetgreen, Inc. owns and operates a chain of salad restaurants. It offers drinks, sides, local bowls, salads, plates, and warm bowls. The company was founded by Nicolas Jammet, Jonathan Neman, and Nathaniel E. Ru in November 2006 and is headquartered in Los Angeles, CA.

Sweetgreen Inc - Ordinary Shares - Class A

Sweetgreen ($SG) is trending as chatter suggests a potential short squeeze ahead of earnings, with community members noting high put/call ratios and significant options activity. Some investors believe the stock is oversold and undervalued, especially given its robotics technology from the SPYCE acquisition, while others are eyeing it as a sympathy play with other heavily shorted stocks like BYND making moves. Community members are actively discussing the potential for a gamma squeeze.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors weigh the potential impact of OpenAI's new web browser, Atlas, on Google's Chrome and search dominance. The community is actively debating whether this poses a real threat to Google's core business, while some view the dip as a buying opportunity, citing Alphabet's strong AI initiatives and attractive valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Equity

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.


Merck (MRK) and Verona Pharma Plc. (VRNA) on Wednesday announced that the two companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma.Merck will <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/">acquire</a> Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.The purchase price represents a 23.2% upside to Verona ADS’s closing price on Tuesday.VRNA shares were trading 21% higher in the pre-market session at the time of writing.London-based Verona is a biopharmaceutical company focused on respiratory diseases.Through the acquisition, <a href="https://stocktwits.com/symbol/MRK">Merck</a> will add Ohtuvayre to its expanding cardiovascular and pulmonary pipeline and portfolio. Ohtuvayre was approved by the U.S. Food and Drug Administration in 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The drug is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis.Ohtuvayre brought in net sales of $71.3 million for Verona in the first quarter of 2025, marking a growth of 95% from the fourth quarter of 2024.The acquisition, Merck said, is expected to drive growth into the next decade.“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders,” Merck CEO Robert M Davis said.The transaction, which was unanimously approved by both the Merck and <a href="https://stocktwits.com/symbol/VRNA">Verona Pharma</a> Boards of Directors, is expected to close in the fourth quarter of 2025.On Stocktwits, retail sentiment around Verona jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’ levels.Retail sentiment around Merck, meanwhile, continues to be in the ‘bearish’ territory, accompanied by ‘normal’ message volume.Shares of VRNA have risen 87% this year while MRK shares have declined nearly 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-climbs-off-multi-year-lows-as-report-unpacks-bessent-influence-on-tariff-timeline/chFUtg2R5i2">Dollar Climbs Off Multi-Year Lows As Report Unpacks Bessent’s Influence On Trump Tariff Timeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Healthcare Leaders ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$54.98
Prev Close	$54.96
Open	$54.98
Dividend Yield	N/A
50-Day Moving Average	$52.08
Beta	N/A
Avg. Volume	111.62
PE Ratio	N/A

52-Week High	$59.68
52-Week Low	$47.67
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

JDOC
JPMorgan Healthcare Leaders ETF

Feed

News

Sentiment

Fundamentals

Info

Latest JDOC News

JDOCJPMorgan Healthcare Leaders ETF